Generating Real World Evidence to Promote Sustainability of Cancer Drug Funding

CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs

Cancer Drug Funding Sustainability: From Recommendations to Action CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs Contributing authors Provincial Drug Reimbursement

Collecting Real World Evidence: HTA s perspective

Collecting Real World Evidence: HTA s perspective Dr. Kelvin Chan, MD FRCPC MSc (Clin Epi) MSc (Biostats) Clinical Lead, Provincial Drug Reimbursement Programs, CCO Co-Director, Canadian Centre for Applied

Phase-specific Net Costs of Cancer Care in Ontario. Claire de Oliveira, M.A. PhD

Phase-specific Net Costs of Cancer Care in Ontario Claire de Oliveira, M.A. PhD Background Cancer: leading cause of death in Canada with costly implications for government and patients Cost estimates of

Real World Cost-Effectiveness of Cancer Drugs

1 Real World Cost-Effectiveness of Cancer Drugs Sara Khor, MASc, Cancer Care Ontario Li Ka Shing Knowledge Institute, St. Michael s Hospital Canadian Centre for Applied Research in Cancer Control April

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

information aligned with the expected toxicity profile of panitumumab, which is well-known as panitumumab is already used as a third-line therapy for patients with mcrc. perc also noted QoL did not deteriorate

Stuart Peacock. Cancer Control Research, BC Cancer Agency Canadian Centre for Applied Research in Cancer Control (ARCC) Simon Fraser University

Stuart Peacock Cancer Control Research, BC Cancer Agency Canadian Centre for Applied Research in Cancer Control (ARCC) Simon Fraser University Advancing Health Economics, Services, Policy and Ethics I

SUMMARY OF perc DELIBERATIONS ON REQUEST FOR ADVICE

SUMMARY OF perc DELIBERATIONS ON REQUEST FOR ADVICE On March 7, 2013, perc issued a reimbursement recommendation for axitinib (Inlyta) for metastatic RCC. On April 18, 2017, the pcodr PAG submitted a Request

compared with those with right-sided tumours. perc also acknowledged contextual information (Arnold et al. and Holch et al.) on the prognostic and predictive effect of tumour sidedness that suggested tumour

Phase-specific Costs of Cancer Care in Ontario

Phase-specific Costs of Cancer Care in Ontario Canadian Association of Health Services and Policy Research Conference Session: D5 Cancer Care Wednesday May 29 2013 Claire de Oliveira, M.A. PhD Background

VALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies?

VALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies? April 24, 2017 Background Therapeutic innovation continues to grow as new therapies

pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception

pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This

information was available on the following: pre-specification of the analysis a priori, sample size calculation and power estimation, stratification t

information was available on the following: pre-specification of the analysis a priori, sample size calculation and power estimation, stratification to ensure balance across treatment groups, and formal

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

Overall, perc considered that everolimus aligned with patient values. Patient advocacy group input on everolimus indicated that patients with pnets value the outcome of progression-free survival as a measure

pan-canadian Oncology Drug Review Final Economic Guidance Report Nab-paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014

pan-canadian Oncology Drug Review Final Economic Guidance Report Nab-paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

Using Administrative Data for Costing: lessons learned

+ Using Administrative Data for Costing: lessons learned Nicole Mittmann, MSc PhD - Executive Director, Health Outcomes and Pharmacoeconomics (HOPE) Research Centre, Sunnybrook Research Institute, Sunnybrook

pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer

pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer May 2, 2013 DISCLAIMER Not a Substitute for Professional Advice

Oncology HTA: Canada versus UK experiences. Isabelle Chabot PhD ARCC Conference - Toronto, 12 May 2014

Oncology HTA: Canada versus UK experiences Isabelle Chabot PhD ARCC Conference - Toronto, 12 May 2014 Disclosure I worked on this analysis while a full-time employee at Pfizer. I am now the Principal at

reconsideration of the perc Initial Recommendation, perc noted that a RCT would likely not be feasible beyond the second-line setting for patients in whom other TKI therapy is not appropriate because of

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer March 3, 2017

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer March 3, 2017 DISCLAIMER Not a Substitute for Professional Advice This report is

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

differ and that they each has a unique mechanism of action. As such perc considered that it would be important for clinicians and patients to be able to choose either drug as a first-line treatment option.

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019 DISCLAIMER Not a Substitute for Professional Advice This report is

Sarah Jennings, BSc, BScPhm, RPh, PharmD Knowledge Mobilization Officer Thursday May 28, 2015 Canadian Pharmacists Conference

Culturing Change in Lab Testing Sarah Jennings, BSc, BScPhm, RPh, PharmD Knowledge Mobilization Officer Thursday May 28, 2015 Canadian Pharmacists Conference CADTH is a health technology assessment (HTA)

at least one dose interruption. perc noted the manufacturer of ponatinib issued a dose reduction recommendation in the PACE study; however, there are currently no data on the optimal starting dose for

Economic Analyses in Clinical Trials

Economic Analyses in Clinical Trials Natasha Leighl (and Nicole Mittmann) Committee on Economic Analysis, NCIC CTG Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca Financial Disclosures Research

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Advanced or Metastatic Non-Small Cell Lung Cancer

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Advanced or Metastatic Non-Small Cell Lung Cancer November 1, 2018 DISCLAIMER Not a Substitute for Professional

pan-canadian Oncology Drug Review Initial Economic Guidance Report Apalutamide (Erleada) for Castration-Resistant Prostate Cancer August 30, 2018

pan-canadian Oncology Drug Review Initial Economic Guidance Report Apalutamide (Erleada) for Castration-Resistant Prostate Cancer August 30, 2018 DISCLAIMER Not a Substitute for Professional Advice This

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017 DISCLAIMER Not a Substitute for Professional Advice This report

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

large impact on cost-effectiveness. perc discussed that one of the main factors affecting the costeffectiveness estimates was the survival estimates used in the economic model. In reviewing the clinical

pan-canadian Oncology Drug Review Final Economic Guidance Report Enzalutamide (Xtandi) for Metastatic Castration-Resistant Prostate Cancer

pan-canadian Oncology Drug Review Final Economic Guidance Report Enzalutamide (Xtandi) for Metastatic Castration-Resistant Prostate Cancer July 23, 2013 DISCLAIMER Not a Substitute for Professional Advice

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

Access to cancer drugs: The role for a stakeholder alliance?

Access to cancer drugs: The role for a stakeholder alliance? John Zalcberg Co-Chair, Cancer Drugs Alliance (CDA) Disclosures Research support, travel support and honoraria from a wide variety of pharmaceutical

Notification to Implement Issued by pcodr: December 14, 2012

PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further

pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016

pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016 DISCLAIMER Not a Substitute for Professional Advice This

Initial Recommendation for Ibrutinib (Imbruvica) for Mantle Cell Lymphoma perc Meeting: June 16, pcodr PAN-CANADIAN ONCOLOGY DRUG REVIEW 4

although ibrutinib was associated with significant improvements in PFS and QoL, adverse events such as fatigue and bleeding were still observed in patients who received ibrutinib. perc concluded that overall,

Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study

Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study Claire de Oliveira PhD, Karen E. Bremner BSc, Reka Pataky MSc, Nadia Gunraj MPH, Mahbubul Haq MSc, Kelvin

OVERALL CLINICAL BENEFIT

cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence

that the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.

pcr in one arm of a randomized clinical trial comparing two neoadjuvant chemotherapies predicts for improved event-free or overall survival in that arm of the clinical trial. perc noted that the NeoALTTO

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of

ARCC CONFERENCE 2017

ARCC CONFERENCE 2017 Canada s Applied Research in Cancer Control Conference CONFERENCE PROGRAM May 25 26, 2017 Toronto, Ontario Hilton Toronto www.cc-arcc.ca THANK YOU TO OUR PARTNERS AND SPONSORS Funding

Committee to Evaluate Drugs (CED)

Committee to Evaluate Drugs (CED) Recommendations and Reasons Document Posted: January 2014 Bevacizumab for recurrent glioblastoma multiforme Product: BEVACIZUMAB (Avastin ) Class of Drugs: vascular endothelial

2. Cost-Effectiveness Analysis

Cost effectiveness of nab-paclitaxel (Abraxane ) + gemcitabine as a combination therapy for metastatic pancreatic cancer in Ireland, eligible for reimbursement as a hospital only product. The National

pan-canadian Oncology Drug Review Initial Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018

pan-canadian Oncology Drug Review Initial Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of

Advancing Health Economics, Services, Policy and Ethics

Economics, personalized health care and cancer control Stuart Peacock Canadian Centre for AppliedResearch incancer Control (ARCC) School of Population and Public Health, University of British Columbia

Patient Group Pathway Model to Accessing Cancer Clinical Trials in Canada

Patient Group Pathway Model to Accessing Cancer Clinical Trials in Canada Barry D. Stein President CCC What problems are we trying to solve? 1. Too few cancer patients are enrolled in clinical trials.

Tamper-Resistant Properties of Drugs Regulations (TRPDR)

Tamper-Resistant Properties of Drugs Regulations (TRPDR) Cost Impact Analysis, 2019 PMPRB presentation to federal, provincial, and territorial public plan representatives on September 29, 2015. 1 Patented

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

well structured and organized, provided perc with a much deeper understanding of patients experiences with relapse or refractory CLL/SLL and its treatment. perc deliberated upon the cost effectiveness

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few

Cancer Care Ontario / Ontario Public Drug Programs

Cancer Care Ontario / Ontario Public Drug Programs Policy: Public funding of cancer drugs and their administration within the context of clinical trials Version: 3.0 Effective Date: December 12, 2016 Replaces

The pcodr review also provided contextual information on ALK mutation testing.

only approximately 4% of NSCLC patients are expected to have the ALK mutation. perc further discussed these estimates in the context of the feasibility of implementing a funding recommendation for crizotinib.

Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?

Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions? 2017 CADTH Symposium Ottawa, April, 24th, 2017 Reiner

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION The pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries of Health (with the exception of

pan-canadian Oncology Drug Review Final Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma November 1, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma November 1, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

for patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to

risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.

risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value

compared to currently available treatment options in the first relapse setting. While perc acknowledged that these trials do not include patients with multiple relapses or patients with refractory disease,

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

perc deliberated upon the cost-effectiveness of lapatinib plus letrozole and discussed the challenges of using letrozole alone as a comparator and/or using trastuzumab plus anastrozole as a comparator.

CITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA

CITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA 29-30 OCTOBER 2016 Making Fair and Sustainable Decisions about Funding for Cancer Drugs in Canada McMaster Health

one patient advocacy group (Myeloma Canada) the submitter (Cancer Care Ontario Hematology Disease Site Group) the manufacturer (Janssen Inc.

perc noted that the pcodr Economic Guidance Panel s estimates of the use of bortezomib in both pre- ASCT and post-asct settings when compared with standard induction therapy and observation-only maintenance

pan-canadian Oncology Drug Review Initial Economic Guidance Report Dacomitinib (Vizimpro) for Non-Small Cell Lung Cancer April 4, 2019

pan-canadian Oncology Drug Review Initial Economic Guidance Report Dacomitinib (Vizimpro) for Non-Small Cell Lung Cancer April 4, 2019 DISCLAIMER Not a Substitute for Professional Advice This report is

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) FINAL RECOMMENDATION Drug: Pralatrexate (Folotyn) The CADTH pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial Ministries

pan-canadian Oncology Drug Review Final Economic Guidance Report Lapatinib (Tykerb) with Letrozole for Metastatic Breast Cancer July 5, 2013

pan-canadian Oncology Drug Review Final Economic Guidance Report Lapatinib (Tykerb) with Letrozole for Metastatic Breast Cancer July 5, 2013 DISCLAIMER Not a Substitute for Professional Advice This report

Patient Values In HTA. CADTH Barry D. Stein April

Patient Values In HTA CADTH Barry D. Stein April 11 2016 About The CCAC Colorectal Cancer Association of Canada ( CCAC ) commenced in 1998 and incorporated in 1999 and continued under the Canada Not For

A rem-arcc-able Update

A rem-arcc-able Update Dr. Jeffrey Hoch 1,4,5 Sarah Benn 1,4 Dr. Stuart Peacock 1,2 Kimberly van der Hoek 1,2 1. Canadian Centre for Applied Research in Cancer Control (ARCC), 2. British Columbia Cancer

perc noted that it was challenging to interpret the data and that limited conclusions could be drawn from these non-comparative trials. The Committee discussed the likelihood of conducting a higher-quality

QoL compared with ADT plus placebo. perc considered this to be reasonable in the nmcrpc setting, where patients QoL is expected to be relatively high and stable. perc discussed that there is a net clinical

pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION

pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The CADTH pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial M inistries of Health (with the exception

Patient Involvement in Drug Coverage Review Ontario Public Drug Programs Patient Evidence Submissions

Patient Involvement in Drug Coverage Review Ontario Public Drug Programs Patient Evidence Submissions Sherry O Quinn A/Senior Manager, Drug Benefits Management Ontario Public Drug Programs Ministry of

pan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016

pan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

perc agreed with the CGP that the tumour responses and toxicities observed in the two non-comparative phase I and II studies compare favourably to cur

perc agreed with the CGP that the tumour responses and toxicities observed in the two non-comparative phase I and II studies compare favourably to currently available palliative chemotherapy options in

Regional Clinical Co-Lead (Physician) Role Opportunity

Regional Clinical Co-Lead (Physician) Role Opportunity The South West Hospice Palliative Care Network (SWHPCN) in partnership with the South West LHIN and the South West Regional Cancer Program are seeking

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study Claire de Oliveira MA PhD, Karen E. Bremner BSc, Reka Pataky

pan-canadian Oncology Drug Review Final Economic Guidance Report Ibrutinib (Imbruvica) for Mantle Cell Lymphoma July 19, 2016

pan-canadian Oncology Drug Review Final Economic Guidance Report Ibrutinib (Imbruvica) for Mantle Cell Lymphoma July 19, 2016 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

limitations of the indirect evidence submitted to pcodr, perc concluded that there is considerable uncertainty on how alectinib compares with ceritinib with regard to outcomes important to decision making

2016 BC Cancer Registry Annual Report

2016 BC Cancer Registry Annual Report Special Focus: Cancer Survivors in British Columbia ABOUT THE BC CANCER AGENCY The BC Cancer Agency, an agency of the Provincial Health Services Authority, provides

THE JOINT/PAN-CANADIAN ONCOLOGY DRUG REVIEW (JODR/pCODR)

THE JOINT/PAN-CANADIAN ONCOLOGY DRUG REVIEW (JODR/pCODR) APPRAISING CANADA S JOINT/PAN-CANADIAN ONCOLOGY DRUG REVIEW (JODR/pCODR) USING AN ECONOMIC PERSPECTIVE By HEATHER MCDONALD, B.Sc., M.Sc. A Thesis

From Macro to Micro What s New and Exciting in Survivorship Care at the BC Cancer Agency

From Macro to Micro What s New and Exciting in Survivorship Care at the BC Cancer Agency Angela Bedard Program Facilitator, Provincial Survivorship Program Helena Daudt Manager of Clinical Research, Vancouver

OVERALL CLINICAL BENEFIT

pcodr systematic review but were excluded from the review because they were retrospective case series. perc confirmed that the inclusion and exclusion criteria of the systematic review were appropriate

Recommendations from Programmatic Review on Disease Pathway Management. Date: June 12, 2010

Recommendations from Programmatic Review on Disease Pathway Management Date: June 12, 2010 Cancer Quality Council of Ontario: Context CQCO founded in 2002 on the recommendations of Ministry review of cancer

status should be eligible for treatment with atezolizumab. perc acknowledged the small number of patients with an EGFR or ALK mutation positive disease recruited on the trials but agreed that the overall

Multiple Criteria HTA Into Practice Local HTA Program. Innovation. Presenter: Paule Poulin, PhD CREATE OR DIE!

Multiple Criteria HTA Into Practice Local HTA Program Innovation CREATE OR DIE! Presenter: Paule Poulin, PhD Authors: P. Poulin, L. Austen et al., Health Technology & Innovation Department of Surgery Calgary

ColonCancerCheck (CCC): Modelling FOBT screening in Ontario for colorectal cancer (CRC) using the Cancer Risk Management Model (CRMM)

ColonCancerCheck (CCC): Modelling FOBT screening in Ontario for colorectal cancer (CRC) using the Cancer Risk Management Model (CRMM) CADTH Panel Presentation April 16, 2012 Toronto Health Economics and

MINISTRY REPONSE TO THE ONTARIO CITIZENS COUNCIL REPORT: INFORMING THE DEVELOPMENT OF A NEW DRUG PROGRAM IN ONTARIO

MINISTRY REPONSE TO THE ONTARIO CITIZENS COUNCIL REPORT: INFORMING THE DEVELOPMENT OF A NEW DRUG PROGRAM IN ONTARIO I would like to extend my thanks to you and the members of the Ontario Citizens Council

Cancer System Quality Index th Annual Launch Event

Cancer System Quality Index 2017 13 th Annual Launch Event MODERATOR: Ruthe Anne Conyngham Member of the Wednesday, May 17, 2017 CSQI 2017 THE RESULTS PRESENTER: Virginia McLaughlin Chair of the Wednesday

patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease

patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease First, perc agreed with CGP that the diagnosis of urothelial

pan-canadian Oncology Drug Review Final Economic Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013

pan-canadian Oncology Drug Review Final Economic Guidance Report Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma August 29, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,

Clinician input indicated that avelumab in second-line treatment would be used following chemotherapy and should be strongly considered as first-line. However, perc noted that avelumab in the first-line

CBCN Year in Review

2016-2017 CBCN Year in Review TABLE OF CONTENTS 03 ADVOCATING FOR CANADIANS AFFECTED BY BREAST CANCER PROVIDING INFORMATION AND EDUCATION 06 11 STRENGTHENING PARTNERSHIPS THE TEAM 15 16 ABOUT CBCN SUPPORTERS

Supporting New Funding Approaches using CIHI s Classification Systems. Health Data Users Day May 27, 2013 Greg Zinck, Manager, Case Mix

Supporting New Funding Approaches using CIHI s Classification Systems. Health Data Users Day May 27, 2013 Greg Zinck, Manager, Case Mix 1 Outline CIHI Groupers and CIHI Data Case Mix, Cost, Case Costing,

Championing Information Management to Improve System Performance and Patient Care

Championing Information Management to Improve System Performance and Patient Care Michael Sherar President and CEO Cancer Care Ontario December 1, 2011 Overview Cancer Care Ontario Elements of Cancer Care

pan-canadian Oncology Drug Review Final Economic Guidance Report Vandetanib (Caprelsa) for Medullary Thyroid Cancer March 30, 2017

pan-canadian Oncology Drug Review Final Economic Guidance Report Vandetanib (Caprelsa) for Medullary Thyroid Cancer March 30, 2017 DISCLAIMER Not a Substitute for Professional Advice This report is primarily

Cancer Imaging Program, Cancer Care Ontario Strategic Directions. Timely Access to Quality Imaging

Cancer Imaging Program, Cancer Care Ontario Strategic Directions Timely Access to Quality Imaging J A N U A R Y 2 0 1 2 Message from Cancer Care Ontario Cancer Care Ontario (CCO) is working in partnership

Evidentiary and Decision Making Challenges in the Context of Rare Diseases Provincial Program Perspective

Evidentiary and Decision Making Challenges in the Context of Rare Diseases Provincial Program Perspective Brent Fraser Director, Drug Program Services Ontario Public Drug Programs Ministry of Health and